WO1990006116A2 - Mittel zur behandlung von chronisch entzündlichen darmerkrankungen - Google Patents

Mittel zur behandlung von chronisch entzündlichen darmerkrankungen Download PDF

Info

Publication number
WO1990006116A2
WO1990006116A2 PCT/EP1989/001426 EP8901426W WO9006116A2 WO 1990006116 A2 WO1990006116 A2 WO 1990006116A2 EP 8901426 W EP8901426 W EP 8901426W WO 9006116 A2 WO9006116 A2 WO 9006116A2
Authority
WO
WIPO (PCT)
Prior art keywords
oxipurinol
alkaline earth
contain
ammonium salts
composition according
Prior art date
Application number
PCT/EP1989/001426
Other languages
German (de)
English (en)
French (fr)
Other versions
WO1990006116A3 (de
Inventor
Ekkehard Scheiffele
Gerhard Gerber
Werner Siems
Andreas Werner
Original Assignee
Henning Berlin Gmbh Chemie- Und Pharmawerk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henning Berlin Gmbh Chemie- Und Pharmawerk filed Critical Henning Berlin Gmbh Chemie- Und Pharmawerk
Priority to AT89912949T priority Critical patent/ATE85522T1/de
Priority to DE8989912949T priority patent/DE58903550D1/de
Publication of WO1990006116A2 publication Critical patent/WO1990006116A2/de
Publication of WO1990006116A3 publication Critical patent/WO1990006116A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • Chronic inflammatory bowel diseases such as Crohn's disease and ulcerative colitis are serious diseases which have a very negative effect on the condition of the patients concerned, which not infrequently lead to incapacity for work and which may require radical surgical measures with the corresponding sequelae.
  • a causal therapy principle is not yet available. Treatment is with sulphalazine or mesalazine and is usually unsatisfactory.
  • corticoids are often required in high doses.
  • so-called superoxide radicals ( ⁇ - radicals) and the lipid peroxidation triggered by them play an important role in the pathogenesis and maintenance of chronic inflammatory bowel diseases. By inhibiting their formation, an effective treatment of the diseases would be given.
  • a significant proportion of the superoxide radicals formed in the intestine are formed in the course of the purine oxidation (formation of uric acid from hypoxanthine and xanthine) by the action of the Dar xanthine oxidase. This can be show the decrease in adenine and guanine nucleotide concentrations.
  • Allopurinol (an inhibitor of xanthine oxidase) has been a standard therapeutic for the treatment of hyperuricaemia and gout for over 20 years. It is converted to a considerable extent in the organism into oxipurinol, which is the main metabolite responsible for the long-term effect of allo-purinol. Occasionally, too Oxipurinol, which is itself poorly absorbable, has already been used to treat gout. It has now been found that, surprisingly, with enteral administration, oxypurinol and / or its alkali, alkaline earth or ammonium salts are suitable for effectively treating chronic inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.
  • Oxipurinol is very sparingly soluble and therefore cannot even be sufficiently absorbed in micronized form to be used as a treatment for hyperuricaemia and gout.
  • the applicant has determined that the alkali and / or alkaline earth salts of oxipurinol in amorphous or crystalline form, which have not yet been described, are obviously already absorbed in the stomach and in the upper region of the small intestine and therefore also for the treatment of hyperuricaemia and gout can be used.
  • the present invention thus relates to agents' for the enteral treatment of inflammatory bowel diseases containing, in addition to conventional carriers and auxiliaries, pharmacologically effective doses of 1 oxypurinol and / or its alkali metal, alkaline earth metal or ammonium salts which only contain the active substance in Release middle and / or lower area of the small intestine or can be used as a clysma.
  • a preferred object of the present invention are agents which are characterized in that they are suitable for oral administration, are enteric-resistant and are only released in the middle and / or lower region of the small intestine. These agents are preferably characterized in that they contain the oxipurinol in the form of alkali and / or alkaline earth metal salts in amorphous or crystalline form and in the form of tablets or capsules resistant to juices.
  • a preferred embodiment of the invention are agents which contain the oxipurinol and / or its alkali metal, alkaline earth metal or ammonium salts in suspended or dissolved form and are in the form of enteric-coated capsules.
  • the invention furthermore relates to compositions which contain the oxipurinol and / or its alkali metal, alkaline earth metal or ammonium salts in solid, suspended or dissolved form and are in the form of clysms.
  • the agents according to the invention which can be used orally generally contain 50 to 800 mg of active ingredient per dose unit.
  • Klysms generally contain 50 to 500 mg of active ingredient per dose unit.
  • the active ingredient must be in a readily soluble form or colloid or disperse.
  • care must be taken that the active ingredient is gastro-resistant and is only released in the middle or lower region of the small intestine.
  • oxypurinol and / or its alkali, alkaline earth "or ammonium salts combine with the previously used agents Sulfasala- zin or mesalazine and bring them to use.
  • Preparations resistant to gastric juice generally have a coating which first dissolves above a pH of 3, preferably only in the pH range from 5 to 7.5, and only releases the active ingredient in the area of the digestive tract in which correspondingly high pH values are available.
  • Suitable coatings are, for example, known coating media such as polymers of acrylic acid
  • oxipurinol in particular their water-dispersible forms and mixtures, and cellulose derivatives such as hydroxypropyl ethyl cellulose and their derivatives, namely Phthalates, acetate succinates or cellulose acetate phthalates.
  • the oxipurinol is only made available in the lower region of the small intestine and in the large intestine, where it effectively inhibits xanthine oxidase and thus prevents the formation of the superperoxide radicals which act as inflammation mediators. It has been shown that oxipurinol and / or its alkali metal, alkaline earth metal or ammonium salts are suitable for the treatment of inflammatory bowel diseases both in the acute phase and for preventing recurrence.
  • the pharmacologically effective doses for oral administration are generally 100 to 800 mg per day and 50 to 500 mg per day for rectal administration.
  • the new alkali and alkaline earth metal salts of oxipurinol are produced in amorphous or crystalline form in a manner known per se. Since they are better and faster soluble than micronized oxipurinol, they make the active ingredient available more quickly and in larger quantities, but at the same time this also leads to increased absorption of the active ingredient in the serum. This may be desirable in patients with hyperuricaemia and gout. However, the special galenical preparation makes it possible to limit the absorption rate. A low absorption of the active substance through the intestinal wall does not interfere, since oxipurinol in the prescribed dose is well tolerated and is renally eliminated.
  • another object of the present invention is the use of oxipurinol and / or its alkali, alkaline earth or ammonium salts for the preparation of agents for the enteral treatment of inflammatory bowel diseases.
  • the invention relates to a method for the enteral treatment of inflammatory bowel diseases by application of pharmacologically effective doses of oxipurinol and / or its alkali metal, alkaline earth metal and / or ammonium salts.
  • the processing of the mother liquor provides a further .15%.
  • the salt is air-resistant and tolerates dry temperatures up to about 70 ° C. Almost quantitative precipitation of oxipurinol from its hot solution is possible with dilute hydrochloric acid (10%).
  • oxipurinol potassium As in Example 2, oxipurinol is suspended in 90% methanol and reacted accordingly with KOH.
  • 113.7 g of oxipurinol sodium according to Example 1 are dry mixed with 30 g of microcrystalline cellulose, 6.0 g of crosslinked 5 polyvinylpyrrolidone and 2.1 g of polyvinylpyrrolidone (average mol. Wt. Approx. 25000), moistened with water
  • the resulting granules are dried and then mixed with 1.2 g of magnesium stearate. Tablets with a diameter of 3 mm and a height of 1.6 mm are pressed from the granules, which are pre-insulated with hydroxypropylmethylcellulose and then coated with an enteric coating of water-dispersible hydroxypropylenemethylcellulose acetate succinate.
  • the film dissolves quickly at a pH value of 7.0 and allows the active ingredient to be released quickly from the dosage form.
  • the film-coated tablets can be filled into hard gelatin capsules. It is also possible to fill the granules in hard gelatin capsules and to coat the finished capsules with gastric juice resistance.
  • Tablets with a weight of 336 mg and a content of 250 mg of oxipurinol sodium are pressed from a tablet granulate according to Example 5.
  • tablets of lower or higher doses can also be produced from these granules.
  • the film dissolves quickly at a pH value of 7.0 and allows the active ingredient to be released quickly from the dosage form.
  • Tablets with a diameter of 2 mm and a height of 1.2 mm are pressed from a tablet granulate according to Example 5 and, after appropriate pre-insulation, in a manner known per se with a film of Eurugite, in particular their water-dispersible form and Mixtures thereof, or a similar film varnish, which delayed release of the active ingredient in the causes passage of the intestine.
  • a gastric juice-resistant film layer according to Example 5 is then applied.
  • the mini-tablets are filled into hard gelatin capsules in an appropriate amount to formulate the required dosage forms.
  • a granulate according to Example 5 is produced. Tablets can be pressed therefrom in a therapy-appropriate dose, preferably 60 to 340 mg per tablet.
  • the tablets are provided with a coating which causes a delayed release in the intestine and additionally with a coating which is resistant to gastric juice.
  • Micronized oxipurinol sodium is added in a 0.1 to 3% sodium carboxymethyl cellulose solution
  • Conventional preservatives such as parahydroxybenzoic acid esters and small amounts of defoamers, preferably silicone defoamers, are suspended in an optionally adjustable concentration, preferably 50 to 500 mg per 100 ml volume, and filled into bottle bottles. _.
  • Micronized oxipurinol sodium is used according to example 10 for the production of clysms.
  • Colitis was induced in 10 rats (body measurements: 200-250 g) by rectal instillation of 25 mg TNB (in 0.25 ml 30% ethanol solution).
  • a group of 10 animals treated in the same way received 5 mg of oxipurinol-Na, which was dissolved in 0.5 ml of glucose solution, orally via an oral tube from the 3rd to the 21st day after the TNB administration at intervals of 8 hours.
  • Another group of 10 animals received only 0.25 ml of the 30% ethanol solution rectally instilled, and another 10 animals served as controls.
  • the intestine (rectum) of the animals treated with TNB showed chronic recurrent grade II - III colitis. In some animals there were incomplete erosions, especially in the areas above the lymph follicles of the surface epithelium, very dense infiltrates in the. Submucosa and abundant perivascular. Mast cells in the surrounding adipose tissue, observed. The animals treated with TNB and oxipurinol-Na showed markedly less pronounced inflammatory features (grade I): a slight increase in lymphocytes and mast cells and a slight edema.
  • Example 13 intestinal samples were examined on the 21st day for the content of purine nucleotides and lipid peroxidation products (thiarbituric acid-reactive substances: TBA-RS).
  • TBA-RS thiarbituric acid-reactive substances
  • the increased concentration of TBA-RS after TNB application is reduced to 46% by adding oxipurinol Na and is therefore even below the control values.
  • Oxipurinol-Na then prevents the TNB-induced drop in adenine and guanine nucleotides and the increased lipid peroxidation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/EP1989/001426 1988-11-25 1989-11-24 Mittel zur behandlung von chronisch entzündlichen darmerkrankungen WO1990006116A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AT89912949T ATE85522T1 (de) 1988-11-25 1989-11-24 Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen.
DE8989912949T DE58903550D1 (de) 1988-11-25 1989-11-24 Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3839839.7 1988-11-25
DE3839839A DE3839839A1 (de) 1988-11-25 1988-11-25 Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen

Publications (2)

Publication Number Publication Date
WO1990006116A2 true WO1990006116A2 (de) 1990-06-14
WO1990006116A3 WO1990006116A3 (de) 1990-08-23

Family

ID=6367891

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1989/001426 WO1990006116A2 (de) 1988-11-25 1989-11-24 Mittel zur behandlung von chronisch entzündlichen darmerkrankungen

Country Status (5)

Country Link
EP (1) EP0445156B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2686566B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE3839839A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2054097T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1990006116A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002567A1 (en) * 2001-06-28 2003-01-09 Astrazeneca Ab New pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections
WO2004056831A1 (en) * 2002-12-20 2004-07-08 Astrazeneca Ab PYRAZOLO [3,4-d] PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF H.PYLORI INFECTION

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083687A1 (en) * 2005-01-28 2006-08-10 Cardiome Pharma Corp. Crystal salt of xanthine oxidase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB975850A (en) * 1955-08-10 1964-11-18 Wellcome Found Xanthine oxidase inhibitors
AT352686B (de) * 1976-03-23 1979-10-10 Spiegl Paul Dr Verfahren zur herstellung von mikrokapseln
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
AU599085B2 (en) * 1986-03-13 1990-07-12 Wellcome Foundation Limited, The Cell protection
CA1297100C (en) * 1986-08-28 1992-03-10 Ryuji Niwa Medicament for curing arteriosclerosis, comprising pyrimido [2,1-b]-benxothiazole derivative

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002567A1 (en) * 2001-06-28 2003-01-09 Astrazeneca Ab New pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections
US7285558B2 (en) 2001-06-28 2007-10-23 Astrazeneca Ab Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections
WO2004056831A1 (en) * 2002-12-20 2004-07-08 Astrazeneca Ab PYRAZOLO [3,4-d] PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF H.PYLORI INFECTION

Also Published As

Publication number Publication date
DE3839839A1 (de) 1990-05-31
JPH04502005A (ja) 1992-04-09
DE58903550D1 (de) 1993-03-25
EP0445156A1 (de) 1991-09-11
JP2686566B2 (ja) 1997-12-08
EP0445156B1 (de) 1993-02-10
ES2054097T3 (es) 1994-08-01
DE3839839C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-12-19
WO1990006116A3 (de) 1990-08-23

Similar Documents

Publication Publication Date Title
DE3751860T2 (de) Verwendung von spezifischem Kernmaterial und Schichten zur Herstellung pharmazeutischer Formulierungen, die stabil gegen die Verfärbung von Omeprazol sind
DE69205971T2 (de) Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten.
EP0032562B1 (de) Neue Dipyridamol-Retardformen und Verfahren zu ihrer Herstellung
DE69807104T2 (de) Formulierungen mit gesteuerter freisetzung
EP0208971B1 (de) Feste Arzneimittelformen zur peroralen Anwendung enthaltend 9-Deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9S)-erythromycin und Verfahren zu ihrer Herstellung
DE60026144T2 (de) Benzamidformulierung mit histon-deacetylase-inhibitoraktivität
DE69212882T2 (de) Gallensäuresalze enthaltende magenstabile pharmazeutische Zusammensetzung zur oralen Verabreichung
DE69500652T2 (de) Nefazodon-Salze mit verbesserter Auflösungsgeschwindigkeit
DE19732903A1 (de) Pellet-Formulierung zur Behandlung des Intestinaltraktes
WO1998000115A2 (de) Stabile arzneiform zur oralen verabreichung und verfahren zu ihrer herstellung
WO1995008323A1 (de) Budesonid-pellets mit kontrolliertem freigabeprofil und verfahren zu ihrer herstellung
DE2351412C2 (de) 2,2-Disubstituierte 1-Oxo-5-indanyloxy-carbonsäuren, Verfahren zu deren Herstellung und Spaltung racemischer Gemische, sowie diese enthaltende Arzneimittel
DD267490A5 (de) Verfahren zur herstellung von wasserfreiem, kristallinem natriumsalz von 5-chlor-3-(2-thenoyl)-2-odindol-1-carboxamid
DE69011618T2 (de) Mundzubereitung zur verabreichung an bestimmter stelle des darmes.
DE60006362T2 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
DE2218147C2 (de) Pharmazeutische Zubereitung
CH654004A5 (de) Kristallmodifikationen des monohydrats und der wasserfreien form von (+)-catechin, verfahren zu deren herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen.
CH658787A5 (de) Pharmazeutische praeparate mit gleichbleibenden elutionseigenschaften.
DE60110118T2 (de) Kristalline glukosaminsulfatmetallsalze und verfahren zu deren herstellung
DE68915269T2 (de) Polyvalentes entzündungshemmendes mittel.
DE10153934A1 (de) Verfahren zur Kristallisation von Profenen
DE3839839C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE19850445A1 (de) Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
DE3830563A1 (de) Orale magnesium und kalium enthaltende praeparate und deren verwendung
EP0130549B1 (de) 5-Aminosalicylsäure-O-sulfate von physiologisch unbedenklichen Basen, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989912949

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989912949

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989912949

Country of ref document: EP